Frequently Asked Questions about AstraZeneca PLC (AZN.L)

Name: AstraZeneca PLC (AZN.L) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does AstraZeneca PLC (AZN.L) do?

Accepted Answer

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology...

Question 2

Is AstraZeneca PLC (AZN.L) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of AZN.L reveals an Altman Z-Score of 3.93 and a Piotroski F-Score of 8/9. These metrics, combined with its 5-year revenue trend ($58.74B most recent), help investors decide if AZN.L fits their risk profile.

Question 3

What is the current P/E ratio for AZN.L?

Accepted Answer

As of the latest trading session, AstraZeneca PLC (AZN.L) has a trailing P/E ratio of 29.98.

Question 4

Who is the CEO of AstraZeneca PLC?

Accepted Answer

The current Chief Executive Officer of AstraZeneca PLC is Pascal Claude Roland Soriot.

Question 5

What was AZN.L's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, AstraZeneca PLC reported annual revenues of $58.74B (2025), $52.94B (2024), $46.58B (2023), $44.25B (2022), $37.11B (2021) respectively.

Question 6

Does AZN.L pay a dividend?

Accepted Answer

AstraZeneca PLC currently pays a dividend to its shareholders, with a trailing dividend yield of 1.58%.

Question 7

How much debt and cash flow does AZN.L have?

Accepted Answer

In its latest reporting period, AstraZeneca PLC generated $8.67B in Free Cash Flow against a total debt load of $29.62B.

Question 8

What is the Price-to-Book (P/B) ratio of AstraZeneca PLC?

Accepted Answer

The Price-to-Book (P/B) ratio for AstraZeneca PLC (AZN.L) is currently 6.39.

Question 9

What is the Price-to-Sales (P/S) ratio of AZN.L?

Accepted Answer

Based on trailing twelve-month data, AstraZeneca PLC (AZN.L) trades at a Price-to-Sales (P/S) ratio of 5.22.

Question 10

What is AstraZeneca PLC's Return on Equity (ROE)?

Accepted Answer

AstraZeneca PLC (AZN.L) has a Return on Equity (ROE) of 23.00%, representing its profitability relative to shareholder equity.

Period	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt
2025-12	114.1B	65.4B	48.7B	29.6B	23.9B
2024-12	104B	63.2B	40.9B	30.1B	24.6B
2023-12	101.1B	62B	39.2B	28.4B	22.6B
2022-12	96.5B	59.4B	37.1B	29.1B	23B
2021-12	105.4B	66.1B	39.3B	30.7B	24.4B

Period	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt
2025-12	114.1B	65.4B	48.7B	29.6B	23.9B
2024-12	104B	63.2B	40.9B	30.1B	24.6B
2023-12	101.1B	62B	39.2B	28.4B	22.6B
2022-12	96.5B	59.4B	37.1B	29.1B	23B
2021-12	105.4B	66.1B	39.3B	30.7B	24.4B